KALA BIO, Inc. (KALA) |
| 0.1917 -0.034 (-15.1%) 04-15 15:59 |
| Open: | 0.2236 |
| High: | 0.2236 |
| Low: | 0.19 |
| Volume: | 3,327,014 |
| Market Cap: | 4(M) |
| PE Ratio: | -0.03 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 0.51 |
| Resistance 1: | 0.37 |
| Pivot price: | 0.19 |
| Support 1: | 0.15 |
| Support 2: | 0.12 |
| 52w High: | 20.6 |
| 52w Low: | 0.146 |
Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.
Financials
| EPS | -5.640 |
| Book Value | -1.170 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -65.8 |
| Return on Equity (ttm) | 0.0 |
Company news
Tue, 14 Apr 2026
Kala Bio rises on plans to leverage AI - MSN
Wed, 01 Apr 2026
Kala Bio engages advisor to review clinical assets, AI analytics - Investing.com
Tue, 31 Mar 2026
Kala Bio (NASDAQ: KALA) notifies SEC of late 2025 10‑K, cites turnover - Stock Titan
Mon, 30 Mar 2026
EXCLUSIVE: Penny Stock Kala Bio Transitions To Revenue Model With AI Platform Launch - Kala Bio (NASDAQ:K - Benzinga
Sun, 22 Mar 2026
If You Invested $1,000 in Kala Pharmaceuticals Inc (KALA) - Stock Titan
Wed, 11 Mar 2026
$180B AI healthcare play: KALA BIO pivots with first agent - Stock Titan
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
